PCSK9 inhibitors: what we know, what we should have understood, and what is to come

Eur Heart J. 2022 Feb 12;43(7):e29-e31. doi: 10.1093/eurheartj/ehz514.

Author

Marc S Sabatine¹

Affiliation

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 31334749
DOI: 10.1093/eurheartj/ehz514

No abstract available

Publication types

Editorial
Comment